CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone908-517-9500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
CorMedix (NASDAQ:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the NASDAQ under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc (NASDAQ:CRMD) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.13 million. View CorMedix's Earnings History.
When is CorMedix's next earnings date?
What price target have analysts set for CRMD?
1 equities research analysts have issued 12-month price objectives for CorMedix's stock. Their predictions range from $6.00 to $6.00. On average, they expect CorMedix's share price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
Has CorMedix been receiving favorable news coverage?
Media stories about CRMD stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CorMedix earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for CorMedix.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Biotest (BIO), Neptune Wellness Solutions (NEPT), Starpharma (SPL), TELIX Pharmaceutical (TLX), Bellus Health (BLU), Oxford BioMedica (OXB), Theratechnologies (TH), ProMetic Life Sciences (PLI), Rafael (RFL), Resverlogix (RVX), Pfenex (PFNX), CEL-SCI (CVM) and 22nd Century Group (XXII).
What other stocks do shareholders of CorMedix own?
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 60)
- Mr. Robert W. Cook, Chief Financial Officer (Age 62)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)
- Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $6.29.
How big of a company is CorMedix?
What is CorMedix's official website?
How can I contact CorMedix?
The company can be reached via phone at 908-517-9500.
MarketBeat Community Rating for CorMedix (NASDAQ CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
